T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

细胞诱导疫苗即使中和抗体滴度较低也能持久预防粘膜 SHIV 感染

阅读:3
作者:Prabhu S Arunachalam #, Tysheena P Charles #, Vineet Joag #, Venkata S Bollimpelli #, Madeleine K D Scott, Florian Wimmers, Samantha L Burton, Celia C Labranche, Caroline Petitdemange, Sailaja Gangadhara, Tiffany M Styles, Clare F Quarnstrom, Korey A Walter, Thomas J Ketas, Traci Legere, Pradeep Bab

Abstract

Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here, we immunized macaques with an HIV envelope trimer, either alone to induce nAbs, or together with a heterologous viral vector regimen to elicit nAbs and cellular immunity, including CD8+ tissue-resident memory T cells. After ten vaginal challenges with autologous virus, protection was observed in both vaccine groups at 53.3% and 66.7%, respectively. A nAb titer >300 was generally associated with protection but in the heterologous viral vector + nAb group, titers <300 were sufficient. In this group, protection was durable as the animals resisted six more challenges 5 months later. Antigen stimulation of T cells in ex vivo vaginal tissue cultures triggered antiviral responses in myeloid and CD4+ T cells. We propose that cellular immune responses reduce the threshold of nAbs required to confer superior and durable protection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。